AbbVie Stock News

AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.

CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premier healthcare incubator and innovation hub, announce the launch of the AbbVie Foundation Health Equity Accelerator. The Accelerator will support the advancement of innovative, scalable solutions and...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then to around $195 now - vs. an increase of about 50% for the S&P 500 over this period.

These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.

Historically, September is a relatively bad month for stock markets. AT&T offers a huge dividend yield and it could start raising the payout again next year.

Consumers are still spending money on healthcare and fast-casual dining. AbbVie is a faithful dividend payer with a blockbuster portfolio.

Abbott Labs produces medications as just one of its revenue sources. AbbVie has shown a knack for expanding the markets of its drugs.

Both of these stocks have something to offer income-seeking investors. AbbVie is moving on from the loss of patent exclusivity for the world's top-selling drug.